Antipsychotic medication and length of stay at a psychiatric maximum-security unit in Norway (1987-2000).
The aim of this study was to evaluate psychopharmacological treatment and the length of stay (LOS) of patients with schizophrenia in a maximum-security psychiatric unit. Data were collected from the hospital files of 82 consecutively admitted patients with schizophrenia who were both admitted and discharged between the years 1987 and 2000. Psychotropic medication and LOS at the time of discharge were registered. Ninety-five per cent of the patients received antipsychotic medication. Zuclopenthixol was the most frequent medication, given to 43% of the patients. Antipsychotic polypharmacy was found in 20% of the cases. Twenty-seven per cent of the patients were medicated with doses above the recommended therapeutic dose range. During the study period, there was no change in the administration and number of psychotropics, but there was an increase in the dosage of antipsychotics. However, LOS was unchanged during the same time. This supports other findings, which suggest that there is no clinical benefit of higher antipsychotic dosage. It is suggested that an optimized medication practice could yield beneficiary effects, not only for schizophrenic symptoms, but also for violence in schizophrenic patients.
Renkel
Sabine
S
Regional sikkerhetsavd, Brøset/St.Olavs Hospital, Trondheim, Norway. sabine.renkel@pst-stfk.no
Rasmussen
Kirsten
K
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003006:Clopenthixol / Q000627:therapeutic use*; D005260:Female; D006760:Hospitalization; D006801:Humans; D007902:Length of Stay; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009664:Norway; D011567:Psychiatric Department, Hospital; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013997:Time Factors; D014754:Violence / Q000517:prevention & control
D014150:Antipsychotic Agents; D003006:Clopenthixol